Percutaneous intervention for the treatment of various cardiac disorders, including coronary artery disease (CAD), peripheral artery disease (PAD), became a well verified technique and has also been recently extended for treating neurovascular disorders such as carotid artery disease. However, distal embolization of various particulate matters such as plaque debris, including fibrin, necrotic atheromatous core, foam cells, cholesterol clefts, and thrombus, at the time of balloon inflation or stent deployment, complicate percutaneous interventions than before. Currently, the risk of distal embolization is considered significant in carotid arteries, degenerated SVG, and thrombotic lesions characterizing the patient affected by acute coronary syndromes. The process of plaque embolization requires a complex interaction that also involves microvascular spasm and thrombosis. Most often, this results in diminished blood flow to the distal vascular bed, potentially complicated by periprocedural ischemia and/or infarction or stroke. In particular, the risk of distal embolization is mainly high in degenerated SVGs, with no reflow being reported in up to 31.8% of cases during the treatment of thrombotic lesions and in up to 7.9% of cases with no thrombus present. However, large particles more than 100 μm may obstruct large, epicardial vessels; very small particles, with 15–50 μm, can also obstruct the microvascular bed causing microinfarcts and left ventricular dysfunction.

1 RESEARCH METHODOLOGY 

2 RESEARCH OBJECTIVES 

3 RESEARCH PROCESS

4 SCOPE & COVERAGE 

5 REPORT ASSUMPTIONS & CAVEATS 

6 MARKET AT A GLANCE 

7 INTRODUCTION 

8 MARKET OPPORTUNITIES & TRENDS 

9 MARKET GROWTH ENABLERS 

10 MARKET RESTRAINTS 

11 MARKET LANDSCAPE